Print
Hyderabad, India. May 11 , 2015  
 

Satish Reddy Appointed as National Safety Council Chairman

Hyderabad, India. May 11 , 2015

Satish Reddy, Chairman of Dr. Reddy’s Laboratories, has been appointed as the new Chairman of the National Safety Council (NSC).

Satish Reddy takes over the Chairmanship from Venu Srinivasan, who steered the workings of the Council since July 2011. The National Safety Council is the apex body set up by the Govt. of India, Ministry of Labour and Employment, to generate, develop and sustain a voluntary movement on Safety, Health and Environment at the national level.

As a part of its mandate to make safety in India a way of life, the council conducts specialized courses and workshops across the nation, carries out safety audits and risk assessments, facilitates awareness camps in organisations and so on.

On his appointment as the Chairman, NSC, Satish Reddy said, “It is an honour and privilege to be nominated as the Chairman of the National Safety Council. The apex body has been doing commendable work since its inception. I look forward to working with my fellow council members in carrying forward key initiatives on health, safety and environment. Safety continues to be a critical factor in contributing to India’s positive growth trajectory”

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com

Disclaimer
This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or re organization , including related integration issues.

The company assumes no obligation to update any information contained herein.

For more information please contact:

Investors Relations
Kedar Upadhye at kedaru@drreddys.com / +91-40-66834297
Saunak Savla at saunaks@drreddys.com / +91-40-49002135
Ashish Girotra (USA) at ashishg@drreddys.com / +1 609-375-9805

Media Relations:
Calvin Printer at calvinprinter@drreddys.com / +91-40- 49002121